Pfizer Return on Average Equity Trend from 2010 to 2022

PFE
 Stock
  

USD 49.75  0.36  0.72%   

Pfizer Return on Average Equity is increasing over the years with slightly volatile fluctuation. Ongoing Return on Average Equity is projected to grow to 33.77 this year. During the period from 2010 to 2022 Pfizer Return on Average Equity anual values regression line had geometric mean of 17.79 and mean square error of  59.03. Pfizer Cost of Revenue is projected to decrease significantly based on the last few years of reporting. The past year's Cost of Revenue was at 9.2 Billion. The current year Gross Profit is expected to grow to about 37.7 B, whereas Earning Before Interest and Taxes EBIT is forecasted to decline to about 18.5 B.
  
Check Pfizer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pfizer main balance sheet or income statement drivers, such as Direct Expenses of 33.3 B, Consolidated Income of 17 B or Cost of Revenue of 9.4 B, as well as many exotic indicators such as Interest Coverage of 15.54, Long Term Debt to Equity of 0.45 or Calculated Tax Rate of 9.19. Pfizer financial statements analysis is a perfect complement when working with Pfizer Valuation or Volatility modules. It can also supplement Pfizer's financial leverage analysis and stock options assessment as well as various Pfizer Technical models . Please check the analysis of Pfizer Correlation against competitors.

Pfizer Return on Average Equity Breakdown

Showing smoothed Return on Average Equity of Pfizer Inc with missing and latest data points interpolated. Return on equity measures a corporation's profitability by calculating the amount of Net Income Common Stock returned as a percentage of [EquityAvg].Pfizer's Return on Average Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pfizer's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 31.87 %10 Years Trend
Increasing
Slightly volatile
   Return on Average Equity   
Share
       Timeline  

Pfizer Return on Average Equity Regression Statistics

Arithmetic Mean 19.71
Geometric Mean 17.79
Coefficient Of Variation 46.68
Mean Deviation 8.12
Median 16.56
Standard Deviation 9.20
Sample Variance 84.63
Range 24.49
R-Value 0.60
Mean Square Error 59.03
R-Squared 0.36
Significance 0.029985
Slope 1.42
Total Sum of Squares 1,016

Pfizer Return on Average Equity History

2012 17.83
2013 27.93
2014 12.38
2015 10.23
2016 11.61
2017 32.57
2018 16.56
2019 25.72
2020 15.22
2021 31.3
2022 33.77

About Pfizer Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Pfizer income statement, its balance sheet, and the statement of cash flows. Pfizer investors use historical funamental indicators, such as Pfizer's Return on Average Equity, to determine how well the company is positioned to perform in the future. Although Pfizer investors may use each financial statement separately, they are all related. The changes in Pfizer's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pfizer's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Pfizer Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Pfizer. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Return on Average Equity 31.30  33.77 
Average Assets146.1 B149.9 B
Average Equity55.5 B59.9 B
Invested Capital Average75.8 B79.2 B
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and womens health under the Premarin family and Eliquis brands biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the ComirnatyBNT162b2, Nimenrix, FSMEIMMUN-TicoVac, Trumenba, and the Prevnar family brands biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, EucrisaStaquis, and Cibinqo brands and amyloidosis, hemophilia, and endocrine diseases under the VyndaqelVyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company Astellas Pharma US, Inc. Myovant Sciences Ltd. Akcea Therapeutics, Inc Merck KGaA Valneva SE BioNTech SE and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Pfizer without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Transaction History Now

   

Transaction History

View history of all your transactions and understand their impact on performance
All  Next Launch Module

Currently Active Assets on Macroaxis

Please check the analysis of Pfizer Correlation against competitors. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Pfizer Stock analysis

When running Pfizer Inc price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.77
Market Capitalization
281.2 B
Quarterly Revenue Growth YOY
0.47
Return On Assets
0.13
Return On Equity
0.37
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine Pfizer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.